Literature DB >> 3317047

A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home.

A O Carter1, A A Borczyk, J A Carlson, B Harvey, J C Hockin, M A Karmali, C Krishnan, D A Korn, H Lior.   

Abstract

In September 1985, an outbreak of Escherichia coli O157:H7 enteritis affected 55 of 169 residents and 18 of 137 staff members at a nursing home. The outbreak was characterized by two phases: a primary wave whose source was probably a contaminated sandwich meal and a secondary wave compatible with person-to-person transmission of infection. Among the elderly residents, the incubation period was 4 to 9 days (mean, 5.7 +/- 1.2). Older age and previous gastrectomy increased the risk of acquiring the infection (P = 0.01 and 0.03, respectively). Antibiotic therapy during exposure was associated with acquiring a secondary infection (P = 0.001). Hemolytic uremic syndrome developed in 12 affected residents (22 percent), 11 of whom died. Overall, 19 (35 percent) of the affected residents died, 17 (31 percent) from causes attributable to their infection. Antibiotic therapy after the onset of symptoms was associated with a higher case fatality rate in the more severe cases, possibly because patients with more severe disease tended to be treated with antibiotics. There were no complications or deaths among the affected members of the staff. Evidence of infection by verotoxin-producing E. coli O157:H7 was detected in 30 of 70 cases on the basis of isolation of this organism or demonstration of free verotoxin in stools. All isolates belonged to the same phage type. The high morbidity and mortality associated with this condition emphasize the need for proper food hygiene, rapid identification of outbreaks of disease, and prompt institution of infection-control techniques among the institutionalized elderly.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317047     DOI: 10.1056/NEJM198712103172403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  112 in total

1.  Escherichia coli infections and hemolytic-uremic syndrome.

Authors:  N Cimolai
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

2.  Performance of Stool-testing Recommendations for Acute Gastroenteritis When Used to Identify Children With 9 Potential Bacterial Enteropathogens.

Authors:  Gillian A M Tarr; Linda Chui; Bonita E Lee; Xiao-Li Pang; Samina Ali; Alberto Nettel-Aguirre; Otto G Vanderkooi; Byron M Berenger; James Dickinson; Phillip I Tarr; Steven Drews; Judy MacDonald; Kelly Kim; Stephen B Freedman
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

3.  Outbreak of Escherichia coli O157:H7 infection in a large family.

Authors:  K Ludwig; H Ruder; M Bitzan; S Zimmermann; H Karch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-03       Impact factor: 3.267

Review 4.  Bacteriophage control of bacterial virulence.

Authors:  Patrick L Wagner; Matthew K Waldor
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

5.  Shiga toxin 2 induces macrophage-granulocyte colonies from human bone marrow and cord blood stem cells.

Authors:  Shin Chiyoda; Tae Takeda; Yosuke Aoki
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 6.  Management of infectious diarrhoea.

Authors:  A C Casburn-Jones; M J G Farthing
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 7.  Infectious diseases and AIDS.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

8.  The Field Epidemiology Training Program at the LCDC.

Authors:  J Hockin
Journal:  Can J Infect Dis       Date:  1991

Review 9.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

10.  Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.

Authors:  L L Cooling; K E Walker; T Gille; T A Koerner
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.